Spring til hovednavigation Spring til søgning Spring til hovedindhold

The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms

  • Mads Emil Bjørn
  • , Hans Carl Hasselbalch

    Abstract

    The inflammation-mediated comorbidities in myelofibrosis (MF) and related neoplasms (MPNs) likely reflect the concurrent immune deregulation and systemic inflammatory nature of the MPNs, emphasizing the link between chronic systemic inflammation, immune deregulation, and the malignant clone. JAK1-2 inhibitors in MF-patients reduce constitutional symptoms and splenomegaly, but also taget autoimmune and inflammation-mediated comorbidities.

    OriginalsprogEngelsk
    TidsskriftAACE clinical case reports
    Vol/bind3
    Udgave nummer6
    Sider (fra-til)499-503
    Antal sider5
    DOI
    StatusUdgivet - jun. 2015

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms'. Sammen danner de et unikt fingeraftryk.

    Citationsformater